metronidazole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiprotozoals and radiosensitizers, metronidazole derivatives 1790 443-48-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metronidazole
  • anagiardil
  • metronidazol
  • metropol
  • metrotab
  • mexibol
  • nidazole
  • trichazol
  • trichobrol
  • metronidazole hydrochloride
  • metronidazole phosphate
  • metronidazole benzoate
  • metronidazole HCl
A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
  • Molecular weight: 171.16
  • Formula: C6H9N3O3
  • CLOGP: -0.46
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 81.19
  • ALOGS: -1.46
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g V
1.50 g P
2 g O
2 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 194.56 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.85 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.96 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 18, 1963 FDA GD SEARLE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 4587.52 31.85 1315 4828 45328 2306614
Clostridium difficile infection 762.06 31.85 182 5961 2708 2349234
Vomiting 555.97 31.85 334 5809 71268 2280674
Nausea 555.10 31.85 394 5749 111795 2240147
Rash 506.66 31.85 295 5848 59263 2292679
Toxic encephalopathy 478.26 31.85 99 6044 719 2351223
Diarrhoea 422.00 31.85 298 5845 83266 2268676
Drug reaction with eosinophilia and systemic symptoms 421.38 31.85 131 6012 5387 2346555
Clostridium difficile colitis 415.96 31.85 105 6038 1974 2349968
Anaphylactic reaction 345.24 31.85 130 6013 9575 2342367
Maternal exposure during pregnancy 334.06 31.85 143 6000 14720 2337222
Pruritus 316.15 31.85 195 5948 43145 2308797
Confusional state 309.86 31.85 158 5985 24186 2327756
Exposure during pregnancy 295.97 31.85 155 5988 25064 2326878
Abortion spontaneous 287.71 31.85 125 6018 13320 2338622
Paraesthesia 279.95 31.85 143 6000 21945 2329997
Drug ineffective 279.17 31.85 254 5889 101370 2250572
Pyrexia 268.61 31.85 191 5952 53517 2298425
Urticaria 261.67 31.85 141 6002 24120 2327822
Abdominal pain 248.62 31.85 154 5989 34220 2317722
Dysgeusia 239.24 31.85 96 6047 8363 2343579
Encephalopathy 233.21 31.85 80 6063 4481 2347461
Dizziness 229.26 31.85 180 5963 58485 2293457
Headache 228.71 31.85 205 5938 79974 2271968
International normalised ratio fluctuation 228.37 31.85 46 6097 285 2351657
Pseudomembranous colitis 221.20 31.85 49 6094 505 2351437
Drug interaction 216.71 31.85 133 6010 29030 2322912
Hepatocellular injury 214.63 31.85 73 6070 3982 2347960
Ataxia 197.71 31.85 61 6082 2431 2349511
Erythema 195.20 31.85 118 6025 25041 2326901
Drug intolerance 194.69 31.85 96 6047 13621 2338321
Toxic epidermal necrolysis 191.80 31.85 63 6080 3081 2348861
Acute generalised exanthematous pustulosis 190.22 31.85 54 6089 1604 2350338
Cerebellar syndrome 186.47 31.85 43 6100 538 2351404
Hypoaesthesia 180.86 31.85 104 6039 20111 2331831
Dysarthria 179.76 31.85 72 6071 6230 2345712
Hypersensitivity 176.16 31.85 108 6035 23485 2328457
Hepatitis 175.91 31.85 71 6072 6266 2345676
Neurotoxicity 172.61 31.85 53 6090 2077 2349865
Malaise 171.82 31.85 149 5994 55436 2296506
Neuropathy peripheral 171.14 31.85 83 6060 11349 2340593
Cholestasis 166.07 31.85 59 6084 3662 2348280
Septic shock 165.22 31.85 70 6073 6984 2344958
Rash macular 153.84 31.85 55 6088 3476 2348466
Condition aggravated 153.09 31.85 111 6032 31868 2320074
Rash maculo-papular 147.47 31.85 56 6087 4196 2347746
Abdominal pain upper 137.02 31.85 90 6053 22010 2329932
Acute kidney injury 126.36 31.85 94 6049 28028 2323914
International normalised ratio increased 124.20 31.85 58 6085 7278 2344664
Asthenia 119.62 31.85 113 6030 46813 2305129
Multiple organ dysfunction syndrome 118.89 31.85 57 6086 7584 2344358
Chromaturia 116.58 31.85 42 6101 2711 2349231
Acute hepatic failure 114.48 31.85 41 6102 2601 2349341
Gait disturbance 114.06 31.85 81 6062 22464 2329478
Angioedema 113.79 31.85 57 6086 8339 2343603
Foetal exposure during pregnancy 112.67 31.85 49 6094 5203 2346739
Swelling face 110.01 31.85 58 6085 9435 2342507
Dyspnoea 106.82 31.85 136 6007 78597 2273345
Infection 103.43 31.85 70 6073 17959 2333983
Hypotension 100.03 31.85 87 6056 32349 2319593
Electrocardiogram QT prolonged 96.99 31.85 50 6093 7764 2344178
Premature baby 96.15 31.85 38 6105 3166 2348776
Muscular weakness 95.51 31.85 62 6081 14835 2337107
Dysphagia 93.83 31.85 58 6085 12747 2339195
Colitis 93.67 31.85 43 6100 5183 2346759
Fatigue 92.79 31.85 132 6011 84741 2267201
Lip swelling 90.60 31.85 41 6102 4780 2347162
Enterocolitis haemorrhagic 90.46 31.85 22 6121 350 2351592
Rash pruritic 90.03 31.85 47 6096 7488 2344454
Neutropenia 90.00 31.85 69 6074 21479 2330463
Pharyngeal oedema 89.57 31.85 37 6106 3456 2348486
Arthralgia 88.50 31.85 103 6040 54182 2297760
Face oedema 88.48 31.85 38 6105 3910 2348032
Thrombocytopenia 85.95 31.85 64 6079 19067 2332875
Swelling 85.55 31.85 60 6083 16290 2335652
Eosinophilia 84.85 31.85 34 6109 2936 2349006
Crohn's disease 83.78 31.85 43 6100 6612 2345330
Therapeutic product effect incomplete 83.04 31.85 50 6093 10481 2341461
Anxiety 83.02 31.85 75 6068 29284 2322658
Polyneuropathy 82.60 31.85 29 6114 1734 2350208
Haemophagocytic lymphohistiocytosis 81.43 31.85 27 6116 1356 2350586
Bloody discharge 81.01 31.85 17 6126 132 2351810
Tachycardia 80.73 31.85 58 6085 16351 2335591
Swollen tongue 80.49 31.85 39 6104 5304 2346638
Nervous system disorder 79.87 31.85 33 6110 3083 2348859
Abdominal discomfort 79.76 31.85 59 6084 17397 2334545
Jaundice 79.36 31.85 39 6104 5469 2346473
Axonal neuropathy 78.68 31.85 17 6126 154 2351788
Decreased appetite 78.15 31.85 72 6071 28819 2323123
Toxicity to various agents 77.89 31.85 76 6067 32678 2319264
Drug-induced liver injury 77.65 31.85 34 6109 3665 2348277
Systemic mastocytosis 77.42 31.85 14 6129 43 2351899
Low birth weight baby 77.32 31.85 23 6120 806 2351136
Candida infection 75.58 31.85 31 6112 2842 2349100
Toxic skin eruption 75.58 31.85 29 6114 2231 2349711
Hallucination 72.93 31.85 42 6101 8106 2343836
Pain 70.13 31.85 98 6045 61759 2290183
Psychotic disorder 70.01 31.85 34 6109 4645 2347297
Vertigo 69.98 31.85 43 6100 9341 2342601
Treatment failure 69.32 31.85 39 6104 7200 2344742
Rash erythematous 67.75 31.85 36 6107 5940 2346002
Disorientation 65.58 31.85 36 6107 6336 2345606
Somnolence 64.40 31.85 59 6084 23426 2328516
Megacolon 64.08 31.85 16 6127 285 2351657
Anaemia 63.38 31.85 70 6073 34722 2317220
Magnetic resonance imaging brain abnormal 62.75 31.85 17 6126 422 2351520
Type IV hypersensitivity reaction 62.59 31.85 18 6125 559 2351383
Vision blurred 61.26 31.85 47 6096 14621 2337321
Acinetobacter infection 61.14 31.85 14 6129 169 2351773
Tremor 60.77 31.85 54 6089 20607 2331335
Anaphylactic shock 60.70 31.85 30 6113 4256 2347686
Agranulocytosis 60.35 31.85 28 6115 3454 2348488
Generalised tonic-clonic seizure 59.87 31.85 32 6111 5340 2346602
Speech disorder 59.66 31.85 34 6109 6430 2345512
Posterior reversible encephalopathy syndrome 59.30 31.85 25 6118 2455 2349487
Lyme disease 58.95 31.85 16 6127 400 2351542
Suicidal ideation 58.69 31.85 41 6102 11046 2340896
Seizure 58.55 31.85 57 6086 24409 2327533
Diverticulitis 58.53 31.85 29 6114 4136 2347806
Dysbiosis 57.62 31.85 11 6132 49 2351893
Weight decreased 56.77 31.85 60 6083 28311 2323631
Chills 56.70 31.85 46 6097 15506 2336436
Clostridial infection 56.70 31.85 18 6125 786 2351156
Fixed eruption 55.46 31.85 13 6130 175 2351767
Pancreatitis acute 54.65 31.85 27 6116 3826 2348116
Paraesthesia oral 54.43 31.85 23 6120 2271 2349671
Gastrointestinal disorder 54.39 31.85 36 6107 8881 2343061
Visual impairment 54.27 31.85 40 6103 11715 2340227
Musculoskeletal stiffness 52.80 31.85 40 6103 12207 2339735
Leukoencephalopathy 52.53 31.85 17 6126 790 2351152
Oedema 52.30 31.85 37 6106 10166 2341776
Haematochezia 51.97 31.85 29 6114 5266 2346676
Staphylococcal infection 51.81 31.85 29 6114 5297 2346645
Peripheral swelling 51.75 31.85 46 6097 17551 2334391
Myalgia 51.45 31.85 52 6091 23281 2328661
Product use in unapproved indication 51.45 31.85 38 6105 11162 2340780
Metabolic acidosis 51.23 31.85 30 6113 5968 2345974
Shock 50.75 31.85 26 6117 3978 2347964
Colitis ulcerative 50.01 31.85 23 6120 2779 2349163
Drug eruption 49.71 31.85 24 6119 3235 2348707
Delirium 49.62 31.85 28 6115 5195 2346747
Muscle haemorrhage 47.94 31.85 15 6128 624 2351318
Blister 47.87 31.85 30 6113 6741 2345201
Leukopenia 47.75 31.85 35 6108 10161 2341781
Leukocytosis 47.59 31.85 24 6119 3552 2348390
Loss of consciousness 47.29 31.85 45 6098 18722 2333220
Insomnia 47.13 31.85 52 6091 25735 2326207
Stevens-Johnson syndrome 46.42 31.85 25 6118 4234 2347708
Burning sensation 46.28 31.85 31 6112 7797 2344145
Pain in extremity 46.06 31.85 66 6077 42474 2309468
Sepsis 45.96 31.85 44 6099 18444 2333498
General physical health deterioration 45.68 31.85 39 6104 14100 2337842
Dermatitis exfoliative 45.37 31.85 17 6126 1224 2350718
Peripheral sensory neuropathy 44.66 31.85 16 6127 1014 2350928
Coma 44.48 31.85 32 6111 9024 2342918
Depressed mood 44.39 31.85 26 6117 5172 2346770
Pancytopenia 44.13 31.85 35 6108 11417 2340525
Faeces discoloured 44.11 31.85 20 6123 2339 2349603
Dysmetria 43.96 31.85 9 6134 61 2351881
Feeling abnormal 43.86 31.85 48 6095 23533 2328409
Depression 43.44 31.85 52 6091 28080 2323862
Chest pain 43.43 31.85 52 6091 28085 2323857
Nystagmus 42.87 31.85 16 6127 1139 2350803
Haemodynamic instability 42.55 31.85 16 6127 1163 2350779
Vitamin K deficiency 42.54 31.85 9 6134 73 2351869
Rash morbilliform 41.99 31.85 13 6130 522 2351420
Epilepsy 41.73 31.85 24 6119 4615 2347327
Hyperbilirubinaemia 41.71 31.85 17 6126 1532 2350410
Vulvovaginal swelling 41.66 31.85 10 6133 150 2351792
Vanishing bile duct syndrome 40.82 31.85 10 6133 164 2351778
Pouchitis 40.76 31.85 9 6134 91 2351851
Abdominal distension 40.50 31.85 32 6111 10379 2341563
Status epilepticus 40.07 31.85 19 6124 2459 2349483
Enterovesical fistula 39.66 31.85 9 6134 104 2351838
Flatulence 39.61 31.85 23 6120 4502 2347440
Retroperitoneal haematoma 39.45 31.85 12 6131 454 2351488
Proctalgia 39.25 31.85 13 6130 650 2351292
Cerebellar ataxia 39.15 31.85 10 6133 196 2351746
Acute psychosis 38.43 31.85 12 6131 496 2351446
Cardiac arrest 37.99 31.85 36 6107 14894 2337048
Disturbance in attention 37.22 31.85 24 6119 5661 2346281
Drug ineffective for unapproved indication 36.83 31.85 19 6124 2947 2348995
Restlessness 36.81 31.85 22 6121 4541 2347401
Hypovolaemic shock 36.64 31.85 13 6130 801 2351141
Enterocolitis 36.24 31.85 13 6130 827 2351115
Pathogen resistance 36.19 31.85 13 6130 830 2351112
Rash papular 35.93 31.85 18 6125 2626 2349316
Airway peak pressure increased 35.83 31.85 7 6136 36 2351906
Dyskinesia 35.82 31.85 22 6121 4767 2347175
Cholecystitis acute 35.78 31.85 14 6129 1134 2350808
Dehydration 35.71 31.85 42 6101 22253 2329689
Hepatitis fulminant 35.39 31.85 12 6131 645 2351297
Haemolytic anaemia 35.33 31.85 16 6127 1865 2350077
Haematuria 35.30 31.85 21 6122 4297 2347645
Neck pain 35.08 31.85 26 6117 7671 2344271
Tongue dry 34.83 31.85 9 6134 185 2351757
Rash pustular 34.82 31.85 15 6128 1552 2350390
Coordination abnormal 34.48 31.85 16 6127 1972 2349970
Dysuria 34.41 31.85 20 6123 3921 2348021
Diplopia 34.06 31.85 19 6124 3446 2348496
Skin lesion 34.02 31.85 20 6123 4005 2347937
Pancreatitis 33.96 31.85 26 6117 8053 2343889
Prothrombin time ratio decreased 33.84 31.85 8 6135 112 2351830
Non-consummation 33.75 31.85 5 6138 1 2351941
Tongue coated 33.62 31.85 9 6134 213 2351729
Palpitations 33.23 31.85 35 6108 16421 2335521
Anorectal ulcer 32.98 31.85 5 6138 2 2351940
Klebsiella infection 32.84 31.85 12 6131 805 2351137
Ureteric obstruction 32.60 31.85 9 6134 240 2351702
Dermatitis bullous 32.12 31.85 14 6129 1490 2350452
Tinnitus 31.95 31.85 21 6122 5114 2346828
Hyporeflexia 31.89 31.85 10 6133 419 2351523

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic encephalopathy 548.51 43.58 108 3403 634 1742636
Neurotoxicity 345.71 43.58 89 3422 1935 1741335
Drug hypersensitivity 343.92 43.58 144 3367 14991 1728279
Encephalopathy 334.84 43.58 103 3408 4349 1738921
Dysarthria 326.14 43.58 105 3406 5154 1738116
Clostridium difficile infection 317.25 43.58 81 3430 1700 1741570
Drug reaction with eosinophilia and systemic symptoms 309.34 43.58 100 3411 4970 1738300
Ataxia 276.41 43.58 77 3434 2276 1740994
Drug ineffective 275.46 43.58 202 3309 63599 1679671
Clostridium difficile colitis 256.63 43.58 67 3444 1537 1741733
Pyrexia 253.63 43.58 170 3341 46230 1697040
Diarrhoea 244.48 43.58 176 3335 53676 1689594
Pseudomembranous colitis 238.43 43.58 51 3460 470 1742800
Cerebellar syndrome 232.00 43.58 50 3461 479 1742791
Paraesthesia 225.40 43.58 96 3415 10355 1732915
Acute kidney injury 204.91 43.58 134 3377 34810 1708460
Septic shock 199.98 43.58 82 3429 8027 1735243
Rash 190.13 43.58 133 3378 38560 1704710
Neuropathy peripheral 179.74 43.58 79 3432 9174 1734096
Vomiting 154.59 43.58 117 3394 38198 1705072
Confusional state 152.93 43.58 93 3418 21185 1722085
Clostridium test positive 147.99 43.58 31 3480 255 1743015
Fixed eruption 147.85 43.58 30 3481 207 1743063
Anaphylactic reaction 144.42 43.58 60 3451 6053 1737217
Cholestasis 143.72 43.58 52 3459 3613 1739657
Renal failure 142.55 43.58 87 3424 19930 1723340
Multiple organ dysfunction syndrome 132.67 43.58 64 3447 9178 1734092
Pathogen resistance 129.39 43.58 36 3475 1053 1742217
Nausea 128.82 43.58 119 3392 51077 1692193
Acute generalised exanthematous pustulosis 128.32 43.58 36 3475 1086 1742184
Cerebellar ataxia 126.11 43.58 26 3485 196 1743074
Toxic epidermal necrolysis 125.15 43.58 42 3469 2329 1740941
Condition aggravated 123.25 43.58 81 3430 21069 1722201
Hepatocellular injury 116.11 43.58 43 3468 3188 1740082
Drug resistance 112.45 43.58 42 3469 3188 1740082
Erythema 109.50 43.58 65 3446 14123 1729147
Agranulocytosis 108.30 43.58 42 3469 3534 1739736
Pruritus 107.06 43.58 77 3434 23145 1720125
Jaundice 102.39 43.58 47 3464 6015 1737255
Anaemia 101.29 43.58 82 3429 29375 1713895
Herpes simplex oesophagitis 100.77 43.58 16 3495 16 1743254
Sepsis 100.12 43.58 69 3442 19369 1723901
Rash maculo-papular 99.88 43.58 40 3471 3663 1739607
Seizure 99.31 43.58 70 3441 20371 1722899
Hepatitis 98.30 43.58 43 3468 4912 1738358
Rash erythematous 97.23 43.58 40 3471 3925 1739345
Thrombocytopenia 96.86 43.58 70 3441 21179 1722091
Nervous system disorder 96.83 43.58 35 3476 2419 1740851
Dysphagia 95.57 43.58 53 3458 10115 1733155
Drug interaction 92.24 43.58 76 3435 27882 1715388
International normalised ratio increased 91.21 43.58 48 3463 8251 1735019
Abdominal pain 89.38 43.58 67 3444 21423 1721847
Urticaria 89.00 43.58 54 3457 12187 1731083
Neutropenia 87.42 43.58 62 3449 18198 1725072
Gait disturbance 87.29 43.58 54 3457 12616 1730654
Swollen tongue 85.07 43.58 33 3478 2775 1740495
Angioedema 84.36 43.58 48 3463 9616 1733654
Nystagmus 83.94 43.58 25 3486 934 1742336
Megacolon 79.52 43.58 19 3492 297 1742973
Metabolic acidosis 79.21 43.58 38 3473 5364 1737906
Candida infection 77.51 43.58 28 3483 1930 1741340
Dizziness 76.82 43.58 75 3436 34286 1708984
Hepatitis cholestatic 76.06 43.58 25 3486 1296 1741974
Colitis 75.57 43.58 34 3477 4146 1739124
Toxicity to various agents 75.42 43.58 69 3442 29072 1714198
Asthenia 74.39 43.58 74 3437 34596 1708674
Long QT syndrome 74.20 43.58 18 3493 301 1742969
Liver function test abnormal 74.13 43.58 37 3474 5689 1737581
Dyspnoea 73.29 43.58 89 3422 51970 1691300
Headache 71.22 43.58 72 3439 34304 1708966
Eosinophilia 71.20 43.58 31 3480 3496 1739774
Leukopenia 71.00 43.58 41 3470 8439 1734831
Pancytopenia 69.68 43.58 45 3466 11312 1731958
Myoclonus 69.61 43.58 27 3484 2268 1741002
Stevens-Johnson syndrome 69.38 43.58 30 3481 3327 1739943
Hepatitis acute 69.21 43.58 23 3488 1234 1742036
Tachycardia 67.70 43.58 46 3465 12582 1730688
Toxic skin eruption 67.39 43.58 25 3486 1858 1741412
Acute hepatic failure 65.40 43.58 25 3486 2018 1741252
Vasculitis 64.13 43.58 23 3488 1552 1741718
Swelling face 64.08 43.58 31 3480 4452 1738818
Coordination abnormal 61.47 43.58 22 3489 1475 1741795
Peripheral sensory neuropathy 60.66 43.58 19 3492 842 1742428
Anaphylactic shock 60.20 43.58 26 3485 2873 1740397
Vertigo 58.54 43.58 29 3482 4384 1738886
Magnetic resonance imaging brain abnormal 58.33 43.58 15 3496 321 1742949
Coma 57.83 43.58 34 3477 7228 1736042
Therapeutic product cross-reactivity 56.94 43.58 14 3497 248 1743022
C-reactive protein increased 56.12 43.58 31 3480 5854 1737416
Clostridial infection 55.66 43.58 17 3494 692 1742578
Pancreatitis acute 54.63 43.58 27 3484 4060 1739210
Blister 54.60 43.58 27 3484 4065 1739205
Rash morbilliform 54.22 43.58 15 3496 428 1742842
Klebsiella infection 53.33 43.58 17 3494 798 1742472
Respiratory failure 53.15 43.58 42 3469 14463 1728807
Skin necrosis 53.14 43.58 17 3494 807 1742463
Haemodynamic instability 52.46 43.58 19 3492 1318 1741952
Infection 52.32 43.58 39 3472 12321 1730949
Disseminated intravascular coagulation 51.67 43.58 25 3486 3589 1739681
Balance disorder 51.02 43.58 29 3482 5783 1737487
Aphthous ulcer 50.42 43.58 16 3495 740 1742530
Treatment failure 49.85 43.58 26 3485 4375 1738895
Inflammation 49.73 43.58 24 3487 3426 1739844
Myocarditis 49.35 43.58 20 3491 1883 1741387
Liver abscess 48.98 43.58 15 3496 616 1742654
Enterococcus test positive 48.95 43.58 11 3500 129 1743141
Linear IgA disease 48.00 43.58 13 3498 342 1742928
Chills 47.51 43.58 36 3475 11651 1731619
Product use in unapproved indication 47.34 43.58 33 3478 9389 1733881
Leukocytosis 46.20 43.58 23 3488 3510 1739760
Lipase increased 45.34 43.58 18 3493 1606 1741664
Torsade de pointes 45.25 43.58 17 3494 1307 1741963
Tachypnoea 45.22 43.58 20 3491 2338 1740932
Botulism 45.09 43.58 8 3503 23 1743247
Pain 44.76 43.58 50 3461 26607 1716663
Disorientation 44.57 43.58 26 3485 5443 1737827
Anal abscess 44.38 43.58 15 3496 847 1742423
Hallucination 44.31 43.58 30 3481 8140 1735130
Palpitations 44.23 43.58 28 3483 6786 1736484
Blood bilirubin increased 44.05 43.58 27 3484 6183 1737087
Functional gastrointestinal disorder 43.76 43.58 12 3499 331 1742939
Oedema 43.73 43.58 28 3483 6920 1736350
Enterococcal infection 43.73 43.58 15 3496 886 1742384

Pharmacologic Action:

SourceCodeDescription
ATC A01AB17 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Antiinfectives and antiseptics for local oral treatment
ATC D06BX01 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
CHEMOTHERAPEUTICS FOR TOPICAL USE
Other chemotherapeutics
ATC G01AF01 GENITO URINARY SYSTEM AND SEX HORMONES
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
Imidazole derivatives
ATC J01XD01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Imidazole derivatives
ATC P01AB01 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
Nitroimidazole derivatives
ATC A02BD01 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BD02 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BD03 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BD11 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BD13 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BD15 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC J01RA03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC J01RA04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC J01RA10 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC P01AB51 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
Nitroimidazole derivatives
FDA EPC N0000175435 Nitroimidazole Antimicrobial
FDA Chemical/Ingredient N0000007663 Nitroimidazoles
CHEBI has role CHEBI:50685 antitrichomonal drug
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:35442 antiparasitic agent
CHEBI has role CHEBI:132992 radiosensitizing agent
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Bacterial septicemia indication 10001005 DOID:0040085
Infection of skin AND/OR subcutaneous tissue indication 19824006
Abscess of liver indication 27916005
Acute amebiasis indication 39224005
Peritonitis indication 48661000
Lower respiratory tract infection indication 50417007
Infection by Trichomonas indication 56335008 DOID:1947
Giardiasis indication 58265007 DOID:10718
Tubo-ovarian abscess indication 58949002
Abdominal abscess indication 75100008
Amebic liver abscess indication 75119003
Endometritis indication 78623009 DOID:1002
Septicemia due to Bacteroides indication 79587009
Infection of bone indication 111253001
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Bacterial endocarditis indication 301183007
Infectious disorder of joint indication 363162000
Rosacea indication 398909004 DOID:8881
Bacterial vaginosis indication 419760006 DOID:3385
Infection due to anaerobic bacteria indication 423451008
Abscess of brain indication 441806004
Peptostreptococcus infection indication 135341000119101
Intra-Abdominal Eubacterium Abscess indication
Skin and Skin Structure Fusobacterium Infection indication
Peptostreptococcus Liver Abscess indication
Skin and Skin Structure Clostridium Infection indication
Clostridium Septicemia indication
Bacteroides Empyema indication
Skin and Skin Structure Peptococcus Infection indication
Bacteroides Endomyometritis indication
Peptostreptococcus Tubo-Ovarian Abscess indication
Intra-Abdominal Anaerobic Abscess indication
Bacteroides Endocarditis indication
Eubacterium Liver Abscess indication
Clostridium Liver Abscess indication
Peptostreptococcus Peritonitis indication
Bacteroides Liver Abscess indication
Bacteroides Peritonitis indication
Bacteroides Tubo-Ovarian Abscess indication
Vaginal Cuff Surgery Post-Op Clostridium Infection indication
Peptococcus Endomyometritis indication
Clostridium Peritonitis indication
B. Fragilis Infections indication
Bacteroides Pneumonia indication
Bacteroides Osteomyelitis indication
Post-Operative Vaginal Cuff Peptostreptococcus Infection indication
Bacteroides Endometritis indication
Intra-Abdominal Bacteroides Abscess indication
Bacteroides Brain Abscess indication
Peptococcus Endometritis indication
Intra-Abdominal Peptostreptococcus Abscess indication
Vaginal Cuff Surgery Post-Op Infection indication
Peptostreptococcus Endomyometritis indication
Clostridium Tubo-Ovarian Abscess indication
Meningitis due to Bacteroides indication
Peptococcus Liver Abscess indication
Peptococcus Tubo-Ovarian Abscess indication
Vaginal Cuff Surgery Post-Op Bacteroides Infection indication
Intra-Abdominal Peptococcus Abscess indication
Prevention of Perioperative Infection indication
Skin and Skin Structure Bacteroides Fragilis Infection indication
Peptococcus Peritonitis indication
Clostridium Endomyometritis indication
Eubacterium Peritonitis indication
Bacteroides Joint Infection indication
Peptostreptococcus Endometritis indication
Vaginal Cuff Surgery Post-Op Peptococcus Infection indication
Intra-Abdominal Clostridium Abscess indication
Clostridium Endometritis indication
Duodenal Ulcer due to H. Pylori indication
Colorectal Perioperative Infection indication
Pyrexia of unknown origin off-label use 7520000
Crohn's disease off-label use 34000006
Balantidiasis off-label use 57725006 DOID:12386
Gas gangrene caused by clostridium perfringens off-label use 266093005
Diverticulitis of gastrointestinal tract off-label use 271366000
Infection by Dracunculus medinensis off-label use 396334002 DOID:14418
Pseudomembranous enterocolitis off-label use 397683000
Helicobacter pylori-associated gastritis off-label use 708164002
Sexual Transmitted Disease Exposure from Sexual Assault off-label use
Periodontal Infections off-label use
Diabetic Foot Infection off-label use
Recurrent Persistent Urethritis off-label use
Alcoholism contraindication 7200002
Lowered convulsive threshold contraindication 19260006
Alcohol intoxication contraindication 25702006
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Disorder of optic nerve contraindication 77157004 DOID:1891
Disorder of brain contraindication 81308009 DOID:936
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Seizure disorder contraindication 128613002
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Non-infective meningitis contraindication 230155003
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Pregnancy, function contraindication 289908002
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Skin irritation contraindication 367466007
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.4 acidic
pKa2 2.68 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1% METROGEL GALDERMA LABS LP N021789 June 30, 2005 RX GEL TOPICAL 6881726 Feb. 21, 2022 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
1% METROGEL GALDERMA LABS LP N021789 June 30, 2005 RX GEL TOPICAL 7348317 Feb. 21, 2022 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
1.3% NUVESSA CHEMO RESEARCH SL N205223 March 24, 2014 RX GEL VAGINAL 8658678 June 27, 2028 TREATMENT OF BACTERIAL VAGINOSIS
1.3% NUVESSA CHEMO RESEARCH SL N205223 March 24, 2014 RX GEL VAGINAL 8946276 June 28, 2032 TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL
1.3% NUVESSA CHEMO RESEARCH SL N205223 March 24, 2014 RX GEL VAGINAL 9198858 June 28, 2032 TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4017836 VUID
N0000146194 NUI
C0025872 UMLSCUI
D00409 KEGG_DRUG
140QMO216E UNII
1032 INN_ID
69198-10-3 SECONDARY_CAS_RN
1222004 SNOMEDCT_US
4017836 VANDF
6922 RXNORM
372602008 SNOMEDCT_US
5105 MMSL
002958 NDDF
4863 MMSL
d00108 MMSL
4173 PUBCHEM_CID
CHEBI:6909 CHEBI
CHEMBL137 ChEMBL_ID
DB00916 DRUGBANK_ID
CHEMBL1200869 ChEMBL_ID
2MN PDB_CHEM_ID
CHEMBL1466172 ChEMBL_ID
D008795 MESH_DESCRIPTOR_UI
CHEMBL2106886 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Flagyl HUMAN PRESCRIPTION DRUG LABEL 1 0025-1821 TABLET, FILM COATED 500 mg ORAL NDA 13 sections
Flagyl HUMAN PRESCRIPTION DRUG LABEL 1 0025-1831 TABLET, FILM COATED 250 mg ORAL NDA 13 sections
Flagyl HUMAN PRESCRIPTION DRUG LABEL 1 0025-1942 CAPSULE 375 mg ORAL NDA 13 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0115-1474 GEL 7.50 mg TOPICAL ANDA 9 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0143-9772 INJECTION, SOLUTION 500 mg INTRAVENOUS ANDA 15 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0168-0275 GEL 7.50 mg TOPICAL ANDA 10 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0168-0323 CREAM 7.50 mg TOPICAL ANDA 10 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0168-0383 LOTION 7.50 mg TOPICAL ANDA 10 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0179-1482 TABLET 500 mg ORAL ANDA 12 sections
Noritate HUMAN PRESCRIPTION DRUG LABEL 1 0187-5202 CREAM 10 mg TOPICAL NDA 10 sections
Vandazole HUMAN PRESCRIPTION DRUG LABEL 1 0245-0860 GEL 7.50 mg VAGINAL NDA 17 sections
METRONIDAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0264-5535 SOLUTION 500 mg INTRAVENOUS NDA 14 sections
METROGEL HUMAN PRESCRIPTION DRUG LABEL 1 0299-3820 GEL 10 mg TOPICAL NDA 16 sections
MetroCream HUMAN PRESCRIPTION DRUG LABEL 1 0299-3836 CREAM 7.50 mg TOPICAL NDA 9 sections
MetroLotion HUMAN PRESCRIPTION DRUG LABEL 1 0299-3838 LOTION 7.50 mg TOPICAL NDA 10 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0338-1055 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 12 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0338-9541 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 12 sections
METRONIDAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0409-7811 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 13 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0440-1795 TABLET 250 mg ORAL ANDA 12 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0440-1796 TABLET 500 mg ORAL ANDA 12 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0615-1576 TABLET 250 mg ORAL ANDA 13 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0615-1577 TABLET 500 mg ORAL ANDA 13 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0615-7693 TABLET 500 mg ORAL ANDA 12 sections
Nuvessa HUMAN PRESCRIPTION DRUG LABEL 1 0642-7466 GEL 65 mg TOPICAL NDA 19 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0713-0633 CREAM 7.50 mg TOPICAL ANDA 10 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0713-0637 GEL 7.50 mg TOPICAL ANDA 9 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0713-0757 CREAM 7.50 mg TOPICAL ANDA 10 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0781-7077 GEL 7.50 mg VAGINAL ANDA 14 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0781-7080 GEL 10 mg TOPICAL ANDA 16 sections
Metronidazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-1453 TABLET 250 mg ORAL ANDA 12 sections